GlassScriptPhysician profile
Anisha Gupta
NPI 1770929846
$58,140.05
in general payments reported to CMS, 2019-2025
60 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,102 · 2020: $2,410 · 2021: $2,323 · 2022: $8,834 · 2023: $1,697 · 2024: $19K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Food and Beverage: $6,460 · Travel and Lodging: $823 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,102.44 |
| Food and Beverage | $6,460.37 |
| Travel and Lodging | $822.52 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $38,211.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Acerus Pharmaceuticals Corporation | $6,010.55 | 2020-2022 | |
| Abbott Laboratories | $2,622.36 | 2019-2025 | Freestyle Libre, Cardiomems |
| Amgen INC. | $1,368.24 | 2019-2025 | Evenity, Tepezza, Repatha |
| Lilly USA, LLC | $992.03 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Corcept Therapeutics | $837.25 | 2019-2025 | Korlym |
| Senseonics, Incorporated | $659.00 | 2019-2025 | Eversense |
| Amneal Pharmaceuticals LLC | $621.58 | 2019-2025 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $510.12 | 2019-2022 | |
| Dexcom, INC. | $466.38 | 2019-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Abbvie INC. | $441.47 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $435.62 | 2019-2025 | |
| Insulet Corporation | $400.21 | 2019-2025 | Omnipod |
| Ascensia Diabetes Care US INC. | $340.34 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.92 | 2019-2025 | Jardiance |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $226.54 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Amarin Pharma, INC. | $222.51 | 2019-2022 | |
| Radius Health, INC. | $221.83 | 2019-2025 | Tymlos |
| Mannkind Corporation | $204.32 | 2019-2023 | Afrezza |
| Medtronic, INC. | $195.25 | 2021-2025 | Venaseal, Minimed 780g, Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $191.00 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Zealand Pharma US, INC. | $190.51 | 2021-2022 | |
| Ibsa Pharma INC. | $189.48 | 2019-2025 | Licart, Tirosint, Flector |
| Merck Sharp & Dohme LLC | $186.48 | 2020-2023 | Steglatro |
| Companion Medical, INC. | $175.52 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $149.42 | 2019-2025 | Strensiq |
| Tandem Diabetes Care, INC. | $141.17 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Globus Medical, INC. | $133.99 | 2025 | Senza |
| Shire North American Group INC | $133.69 | 2019 | |
| Merz Pharmaceuticals, LLC | $113.73 | 2025 | Xeomin |
| Medtronic Minimed, INC. | $103.68 | 2019-2020 | |
| Esperion Therapeutics, INC. | $103.36 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.84 | 2022-2025 | |
| Cequr Corporation | $68.29 | 2023-2025 | Cequr Simplicity |
| Madrigal Pharmaceuticals | $67.89 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $62.49 | 2025 | Yorvipath |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.38 | 2020-2023 | Cycloset |
| Ultragenyx Pharmaceutical INC. | $50.16 | 2020-2022 | |
| Alvogen INC | $48.66 | 2025 | Teriparatide |
| Novartis Pharmaceuticals Corporation | $47.15 | 2022 | |
| Beta Bionics, INC. | $46.38 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Pfizer INC. | $43.83 | 2022 | |
| Currax Pharmaceuticals LLC | $43.11 | 2021-2023 | Contrave |
| Tolmar, INC. | $41.91 | 2023-2025 | Jatenzo |
| Sequel Med Tech, LLC | $40.27 | 2025 | Twiist |
| Vivus LLC | $35.20 | 2021 | |
| Verity Pharmaceuticals INC. | $34.33 | 2024 | Tlando |
| Janssen Pharmaceuticals, INC | $28.80 | 2019 | |
| Vistapharm, INC. | $26.33 | 2021 | |
| Neurocrine Biosciences, INC. | $24.85 | 2025 | |
| Horizon Therapeutics Plc | $23.13 | 2022 | |
| Avion Pharmaceuticals | $23.07 | 2023 | NP Thyroid 60 |
| Intuity Medical INC | $22.06 | 2022 | |
| Vertical Pharmaceuticals, LLC | $19.43 | 2019 | |
| Almatica Pharma LLC | $16.57 | 2025 | Teriparatide |
| Endo Pharmaceuticals INC. | $15.91 | 2020 | |
| Shield Therapeutics INC | $14.07 | 2024 | |
| Halozyme INC | $13.08 | 2023 | |
| Arbor Pharmaceuticals, INC. | $12.74 | 2021 | |
| Allergan, INC. | $12.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anisha Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.